Author:
Diniz Gulden,Düzenli Neslihan,Ertem Ozge,Ozyilmaz Berk
Publisher
Springer International Publishing
Reference50 articles.
1. Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal muscular atrophy. Semin Pediatr Neurol. 2021;37:100878.
2. Spinraza [product information]. Cambridge, MA: Biogen, 2017; [Last updated Feb 02 2022; cited Jun 20 2022]. https://www.ema.europa.eu/en/documents/product-information/spinraza-epar-product-information_en.pdf.
3. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723–32.
4. Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625–35.
5. De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842–56.